ArticleBiochemistry and biophysics reports2026
Unveiling ELAVL1 as a key RNA-binding protein regulating the chemokine signaling pathway in diabetic nephropathy.
Article in Biochemistry and biophysics reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The ELAVL1-PLAUR-suPAR Axis Exacerbates Diabetic Nephropathy by Promoting Podocyte Injury and Inflammation.Journal of diabetes · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The chemokine signaling pathway is a key factor in inflammation and the development of diabetic nephropathy (DN). The involvement of RNA-binding proteins (RBPs) in modulating this pathway is not yet fully clarified. This study aimed to examine the regulatory role of RBPs in the chemokine signaling pathway associated with DN. Using transcriptional data from the GSE142153 dataset, DEGs were identified. By intersecting DN-associated DEGs with chemokine pathway genes from the MSigDB database, 30 common genes were identified. Four hub genes were then selected through PPI network analysis. Target RBPs of these hub genes were predicted using the RNAInter database, with ELAVL1 identified as a shared regulatory RBP. The expression of ELAVL1 was further validated in the GSE142025 dataset. ELAVL1 gene expression was measured in 90 PBMC samples from three groups: T2D patients, DN patients, and healthy controls, with 30 individuals in each group. Real-time PCR results demonstrated a significant upregulation of ELAVL1 in DN patients versus T2D and control groups. This study highlights the critical role of ELAVL1 in promoting inflammation through the chemokine signaling pathway and contributing to renal injury. Thus, ELAVL1 could be considered a valuable biomarker for identifying and tracking the development of DN.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.